Expression and Clinical Significance of Syndecan-1 Protein in Gastric Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

TAN Ming ¹ , DAI Chun ¹ , DING Yongbin ² , XIA Jianguo ²

1.Department of General Surgery, The People’s Hospital of Yangzhong City, Yangzhong 212200, Jiangsu Province, China;;
2.Department of Gastrointestinal Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;

Corresponding author：

Keywords：

Gastric carcinoma; Syndecan-1 protein; Lymph node metastasis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of syndecan-1 protein in gastric carcinoma and normal gastric mucosa tissues, and find out the correlation between the expression of syndecan-1 protein and the clinicopathologic characteristics of gastric carcinoma. Methods The expression of syndecan-1 protein was detected by immunohistochemistry (ABC) in 60 cases of gastric carcinoma, including gastric carcinoma tissues and normal gastric mucosa tissues. Results Syndecan-1 protein expressed in all of the 60 normal gastric mucosa tissues, however, only 10 of 60 gastric carcinoma tissues (16.67%) showed positive expression. The positive rate of syndecan-1 expression in normal gastric mucosa tissues was higher than that in gastric carcinoma tissues, and this difference was statistically significant (χ2=65.88, P＜0.05). The expression level of syndecan-1 protein in gastric carcinoma tissues with lymph node metastasis was lower than that without lymph node metastasis, and this difference was also statistically significant (χ2 =18.62, P＜0.05). In addition, syndecan-1 expression was not correlated with patients’ age and position of tumor (P gt;0.05), but correlated with the diameter， invasion depth and TNM stage of tumor (P lt;0.05). Conclusion The positive expression of syndecan-1 protein is low in gastric carcinoma tissue and has b correlation with tumor stage and lymph node metastasis.

Citation： TAN Ming,DAI Chun,DING Yongbin,XIA Jianguo. Expression and Clinical Significance of Syndecan-1 Protein in Gastric Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2008, 15(12): 910-913. doi: Copy

1.	Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans [Ｊ]. Annu Rev Cell Biol, 1992; 8∶ 365.
2.	史伟峰, 陈同钰, 张学光. CD138分子生物学特性与肿瘤关系的研究进展 [Ｊ]. 国外医学·临床生物化学与检验学分册, 2002; 23(1)∶ 39.
3.	Yoo CH, Noh SH, Kim YI, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma.International Union Against Cancer [Ｊ]. World J Surg, 1999; 23(5)∶ 492.
4.	Kaushal GP, Xiong X, Athoto AB, et al. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9 [Ｊ]. Br J Haematol, 1999; 104(2)∶ 365.
5.	Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas [Ｊ]. Diagn Cytopathol, 2005; 33(2)∶ 65.
6.	Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies [Ｊ]. Exp Oncol, 2007; 29(1)∶ 54.
7.	冯云路，肖毅，钱家鸣，等. syndecan-1在结直肠癌中的表达及意义 [Ｊ]. 中国普外基础与临床杂志, 2007; 14(3)∶ 320.
8.	Huang MF, Zhu YQ, Chen ZF, et al. Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer [Ｊ]. World J Gastroenterol, 2005; 11(19)∶ 2975.
9.	席银雪，宁鑫，陈洁，等. Syndecan-1在胃黏膜癌变不同阶段组织中的表达及意义 [Ｊ]. 中华肿瘤杂志, 2007; 29(3)∶ 193.
10.	Watari J, Saitoh Y, Fujiya M, et al. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 104.
11.	Hayashi K, Hayashi M, Jalkanen M, et al. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study [Ｊ]. J Histochem Cytochem, 1987; 35(10)∶ 1079.
12.	Hirabayashi K, Numa F, Suminami Y, et al. Altered proliferative and metastatic potential associated with increased expression of syndecan-1 [Ｊ]. Tumour Biol, 1998; 19(6)∶ 454.
13.	茹国庆，赵仲生，汤琪乐，等. Syndecan-1和乙酰肝素酶mRNA表达与胃癌转移和预后的关系 [Ｊ]. 中华外科杂志, 2006; 44(15)∶1062.
14.	Peretti T, Waisberg J, Mader AM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma [Ｊ]. Eur J Gastroenterol Hepatol, 2008; 20(8)∶ 756.
15.	Roh YH, Kim YH, Choi HJ, et al. Syndecan-1 expression in gallbladder cancer and its prognostic significance [Ｊ]. Eur Surg Res, 2008; 41(2)∶ 245.
16.	王学浩，成峰，钱建民，等. syndecan-1蛋白的表达与肝细胞肝癌恶性表型的研究 [Ｊ]. 中国普外基础与临床杂志, 2001; 8(4)∶ 239.
17.	Wiksten JP, Lundin J, Nordling S, et al. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer [Ｊ]. Oncology, 2005; 68(4-6)∶ 306.
18.	Wiksten JP, Lundin J, Nordling S, et al. A prognostic value of syndecan-1 in gastric cancer [Ｊ]. Anticancer Res, 2000; 20(6D)∶ 4905.
19.	Oguri K, Okayama M. Can syndecan-1 become a prognostic factor in solid tumors? [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 197.

1. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans [Ｊ]. Annu Rev Cell Biol, 1992; 8∶ 365.
2. 史伟峰, 陈同钰, 张学光. CD138分子生物学特性与肿瘤关系的研究进展 [Ｊ]. 国外医学·临床生物化学与检验学分册, 2002; 23(1)∶ 39.
3. Yoo CH, Noh SH, Kim YI, et al. Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma.International Union Against Cancer [Ｊ]. World J Surg, 1999; 23(5)∶ 492.
4. Kaushal GP, Xiong X, Athoto AB, et al. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9 [Ｊ]. Br J Haematol, 1999; 104(2)∶ 365.
5. Saqi A, Yun SS, Yu GH, et al. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas [Ｊ]. Diagn Cytopathol, 2005; 33(2)∶ 65.
6. Mitselou A, Ioachim E, Peschos D, et al. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies [Ｊ]. Exp Oncol, 2007; 29(1)∶ 54.
7. 冯云路，肖毅，钱家鸣，等. syndecan-1在结直肠癌中的表达及意义 [Ｊ]. 中国普外基础与临床杂志, 2007; 14(3)∶ 320.
8. Huang MF, Zhu YQ, Chen ZF, et al. Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer [Ｊ]. World J Gastroenterol, 2005; 11(19)∶ 2975.
9. 席银雪，宁鑫，陈洁，等. Syndecan-1在胃黏膜癌变不同阶段组织中的表达及意义 [Ｊ]. 中华肿瘤杂志, 2007; 29(3)∶ 193.
10. Watari J, Saitoh Y, Fujiya M, et al. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 104.
11. Hayashi K, Hayashi M, Jalkanen M, et al. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study [Ｊ]. J Histochem Cytochem, 1987; 35(10)∶ 1079.
12. Hirabayashi K, Numa F, Suminami Y, et al. Altered proliferative and metastatic potential associated with increased expression of syndecan-1 [Ｊ]. Tumour Biol, 1998; 19(6)∶ 454.
13. 茹国庆，赵仲生，汤琪乐，等. Syndecan-1和乙酰肝素酶mRNA表达与胃癌转移和预后的关系 [Ｊ]. 中华外科杂志, 2006; 44(15)∶1062.
14. Peretti T, Waisberg J, Mader AM, et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma [Ｊ]. Eur J Gastroenterol Hepatol, 2008; 20(8)∶ 756.
15. Roh YH, Kim YH, Choi HJ, et al. Syndecan-1 expression in gallbladder cancer and its prognostic significance [Ｊ]. Eur Surg Res, 2008; 41(2)∶ 245.
16. 王学浩，成峰，钱建民，等. syndecan-1蛋白的表达与肝细胞肝癌恶性表型的研究 [Ｊ]. 中国普外基础与临床杂志, 2001; 8(4)∶ 239.
17. Wiksten JP, Lundin J, Nordling S, et al. Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer [Ｊ]. Oncology, 2005; 68(4-6)∶ 306.
18. Wiksten JP, Lundin J, Nordling S, et al. A prognostic value of syndecan-1 in gastric cancer [Ｊ]. Anticancer Res, 2000; 20(6D)∶ 4905.
19. Oguri K, Okayama M. Can syndecan-1 become a prognostic factor in solid tumors? [Ｊ]. J Gastroenterol, 2004; 39(2)∶ 197.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression and Clinical Significance of Syndecan-1 Protein in Gastric Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content